Table 4.
Pretreatment and posttreatment characteristics of IGT patients with hypertriglyceridemia treated with fenofibrate
| Parameters | Pretreatment (n = 118) |
Posttreatment (n = 118) |
P value |
|---|---|---|---|
| BMI (kg/m2) | 26.47 ± 4.68 | 26.43 ± 4.59 | 0.176 |
| SBP (mmHg) | 127.51 ± 6.04 | 127.94 ± 6.58 | 0.158 |
| DBP (mmHg) | 75.50 ± 6.49 | 75.59 ± 6.53 | 0.806 |
| TC (mmol/L) | 5.13 ± 1.04 | 4.85 ± 0.86 | 0.001 |
| HDL-C (mmol/L) | 1.34 ± 0.28 | 1.44 ± 0.33 | <0.001 |
| LDL-C (mmol/L) | 3.10 ± 0.74 | 2.91 ± 0.67 | 0.003 |
| TG (mmol/L) | 2.37 (1.99, 2.81) | 1.62 (1.16, 1.97) | <0.001 |
| FFA (mmol/L) | 0.67 ± 0.18 | 0.45 ± 0.16 | <0.001 |
| hsCRP (mg/L) | 1.64 (1.04, 2.57) | 1.28 (0.53, 2.05) | 0.004 |
| CR (μmol/L) | 67.56 ± 17.26 | 72.03 ± 16.42 | 0.001 |
| AST (IU/L) | 21.00 (17.00, 24.00) | 20.00 (18.00, 25.00) | 0.446 |
| ALT (IU/L) | 22.00 (18.75, 28.00) | 22.00 (17.00, 28.00) | 0.351 |
| CK (IU/L) | 84.00 (66.00, 114.50) | 78.00 (63.00, 111.50) | 0.911 |
| FBG (mmol/L) | 6.33 ± 0.49 | 6.27 ± 0.49 | 0.123 |
| 2hPG (mmol/L) | 9.34 ± 0.88 | 9.18 ± 0.74 | 0.092 |
| HbA1c (%) | 6.30 (6.00, 6.40) | 6.30 (6.00, 6.40) | 0.777 |
| FINS (mIU/L) | 15.50 (10.78, 18.60) | 13.10 (9.90, 16.43) | <0.001 |
IGT impaired glucose tolerance, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglycerides, FFA free fatty acids, hsCRP high sensitivity C-reactive protein, CR creatinine, AST aspartate aminotransferase, ALT alanine aminotransferase, CK creatine kinase, FBG fasting blood glucose, 2hPG 2-h postchallenge glucose, HbA1c glycosylated hemoglobin, FINS fasting insulin